
    
      Eligible adult patients (>= 13 years of age) will receive treatment with Viramune once daily
      for 2 weeks and then twice daily. Eligible pediatric patients (< 13 years of age) will
      receive a lower dose of Viramune once daily for 2 weeks and then twice daily. All patients
      will receive Viramune with or without concomitant antiretroviral therapy. Patients will be
      evaluated at weeks 2, 4, 8, 16, 24, 32 and every 8 weeks thereafter.

      PER AMENDMENT 01/31/97: Enrollment closed to adult patients. As of 1/31/97 only enrolling
      pediatric patients.
    
  